BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• BioMidwest

  Myriad’s BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients With Improved Outcomes From Pfizer’s PARP Inhibitor, Talazoparib

  Myriad’s BRACAnalysis CDx test successfully identified patients with metastatic breast cancer (MBC) who responded to Pfizer’s investigational PARP inhibitor, talazoparib.

  December 12, 2017

   · 

  7 min read
• 

  Policy

  FDA Delays Action Date for Pfizer’s Xeljanz sNDA App by Three Months

  The FDA has provided an anticipated PDUFA date in June 2018.

  December 12, 2017

   · 

  14 min read
• 

  Virtual Incision Bags $18M for Miniaturized Surgical Robots

  The cash will support the company’s 510(k) premarket notification submission to the FDA for its next-generation miniaturized robotically assisted surgical device.

  December 12, 2017

   · 

  4 min read
• ESSA Pharma Announces Overnight Marketed Offering

  The Offering will be conducted in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to ESSA’s base shelf prospectus dated December 22, 2015 and elsewhere on a private placement basis.

  December 12, 2017

   · 

  4 min read
• Helix BioPharma Corp. Announces Voting Results From Annual and Special Meeting of Shareholders

  Helix BioPharma announced today the results of matters voted on at its annual and special meeting of shareholders held on December 12, 2017

  December 12, 2017

   · 

  4 min read
• Genetown

  bluebird bio Announces Pricing of 3,243,244 Shares of Public Offering of Common Stock

  bluebird bio announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share, before underwriting discounts.

  December 12, 2017

   · 

  6 min read
• Business

  Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration With Major Cancer Center in HER2-Mutated Cancer

  Daiichi Sankyo and Puma Biotechnology will co-sponsor the research.

  December 12, 2017

   · 

  12 min read
• Policy

  California Life Sciences Association Commends New Legislation to Suspend Medical Device Tax

  California Life Sciences Association applauded the introduction of H.R. 4617, which suspends until December 2022 the job and innovation destroying 2.3% medical device excise tax levied on medical device firms originally established as part of the Affordable Care Act.

  December 12, 2017

   · 

  2 min read
• Drug Development

  Preliminary Data From Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

  These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population.

  December 12, 2017

   · 

  9 min read
• Genetown

  Blueprint Medicines, Corp. Announces Pricing of Public Offering of Shares of Common Stock

  Blueprint Medicines today announced the pricing of an underwritten public offering of 3,703,704 shares of its common stock at a public offering price of $81.00 per share, before underwriting discounts and commissions.

  December 12, 2017

   · 

  4 min read